Clinical trials: Hepatic Chemotherapy
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for…
- Trial name
- NCT05751343
- Testing
- TACE-HACI, plus atezolizumab-bevacizumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Influence of Neoadjuvant Therapy on the Resectability of Hepatic Metastases From Colorectal Cancers
More and more colorectal surgeons believe that surgical resections of hepatic metastases from colorectal cancer is the only chance for cure of patients.
- Trial name
- NCT00172159
- Testing
- Hepatic resection
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases
Currently, no adjuvant study with hepatic arterial infusion in the adjuvant setting is opened. Recently, the results of a phase II study (NCT00268463, NSABP-C-09) assessing the potential benefit of systemic oxaliplatin and…
- Trial name
- PACHA-01 (NCT02494973)
- Testing
- Oxaliplatin HAI, Oxaliplatin IV, mFOLFOX6
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hepato Cellular Carcinoma (HCC)
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
This is a single-arm, phase II clinical trial evaluating the safety and efficacy of PD-L1 antibody combined with bevacizumab and hepatic arterial infusion chemotherapy (HAIC) for patients with advanced unresectable hepatocellular…
- Trial name
- NCT06742424
- Testing
- PD-L1 antibody, Bevacizumab, HAIC-FOLFOX
- Where
- China
- Volunteers
- 36 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma Non-resectable
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
This is an open-label, single-arm, phase 2 study evaluating hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and cadonilimab as conversion therapy for initially unresectable hepatocellular carcinoma (HCC).
- Trial name
- CCGLC-011 (NCT06187961)
- Testing
- Hepatic arterial infusion chemotherapy (HAIC-FOLFOX), Lenvatinib, Cadonilimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
HCC
DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial
This is a randomized controlled trial to determine the efficacy and safety of DEB-TACE versus DEB-TACE sequential HAIC for unresectable BCLC stage C HCC
- Trial name
- NCT05788835
- Testing
- DEB-TACE and HAIC, DEB-TACE
- Where
- 16 sites in China
- Volunteers
- 220 people
- Sponsor
- Xuhua Duan
Colorectal Cancer, Metastatic Cancer
Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544349
- Testing
- cetuximab, fluorouracil, leucovorin calcium
- Where
- 7 sites in France
- Volunteers
- 45 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant…
- Conditions
- Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma
- Trial name
- NCT07845617
- Testing
- Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AdventHealth
Hepatocellular Carcinoma
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
This is a prospective, single-armed, multicentric, explorative phase II clinical research of conversional therapy with combination of hepatic arterial infusion chemotherapy(HAIC), Donafenib Tosilate and Toripalimab for…
- Trial name
- NCT05493332
- Testing
- HAIC(FOLFOX), Oxaliplatin, Leucovorin
- Volunteers
- 93 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastroesophageal Varices Hemorrhage, Gastrointestinal Cancer
Management of Oxaliplatin-related Gastroesophageal Variceal Bleeding
In this randomized controlled study, we aim to compare the efficacy and safety of these two interventions in patients with oxaliplatin-induced gastroesophageal variceal bleeding.
- Conditions
- Gastroesophageal Varices Hemorrhage, Gastrointestinal Cancer, Received Oxaliplatin-based Chemotherapy
- Trial name
- NCT05141617
- Testing
- Endoscopic treatment, TIPS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Our previous study showed that hepatic arterial infusion chemotherapy plus lenvatinib and toripalimab improved the survival of advanced hepatocellular carcinoma.
- Trial name
- NCT06201065
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Pancreatic Adenocarcinoma, Liver Metastases
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma.
- Trial name
- NCT03856658
- Testing
- Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corewell Health West
Hepatocellular Carcinoma
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
This is an open, single-arm clinical study to observe and evaluate the efficacy and safety of first-line treatment of patients with stage C hepatocellular carcinoma of BCLC at HAIC in combination with adebrelimab and apatinib.
- Trial name
- NCT06482008
- Testing
- Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib
- Volunteers
- 33 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from cancer. Between 30 to 60% of patients develop limited or predominant liver metastases.
- Trial name
- OSCAR (NCT02885753)
- Testing
- Oxaliplatin intravenous, 5 FU bolus, Folinic acid
- Where
- 49 sites in Belgium, France
- Volunteers
- 348 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Hepatic Arterial Infusion Chemotherapy, Liver Metastases
HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
Patients with liver metastasis from esophagus squamous (ESC) are usually offered systemic therapy. However, for those with predominant liver disease or failure of system therapy, local liver management becomes an option.
- Conditions
- Hepatic Arterial Infusion Chemotherapy, Liver Metastases, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06184841
- Testing
- HAIC combined with intravenous PD-1
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University Cancer Hospital & Institute
Biliary Tract Cancer
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
This prospective real-world study aims to evaluate the effectiveness and safety of an alternating treatment regimen combining hepatic arterial infusion chemotherapy (HAIC) with systemic chemotherapy, with or without adebrelimab…
- Trial name
- NCT07569679
- Testing
- HAIC, Gemcitabine plus Cisplatin, Adebrelimab
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Air Force Military Medical University, China
Bile Duct Cancer
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
The goal of this clinical trial is to provide evidence for the general tolerability of radiofrequency ablation (bRFA) in patients with unresectable bile duct cancer undergoing systemic palliative treatment consisting of systemic…
- Trial name
- Ablatio (NCT06274879)
- Testing
- Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting
- Where
- 4 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatecellular Carcinoma, Liver Injury
HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival
The purpose of this study is to compare the liver injury induced by HAIC combined with PD-1/PD-L1 inhibitors and TKIs versus triple therapy with TACE in the treatment of patients with advanced HCC; to compare the efficacy of the…
- Conditions
- Hepatecellular Carcinoma, Liver Injury, HAIC(Hepatic Artery Infusion Chemotherapy), TACE(Transcatheter Arterial Chemoembolization)
- Trial name
- NCT07277192
- Where
- China
- Volunteers
- 562 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cancer
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Targeted Therapy and a PD-1 Inhibitor in Patients with Postoperative Hepatocellular Carcinoma…
- Trial name
- NCT07790419
- Testing
- HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhai Wenlong